Current partner codePEPTIDESDE
NCT02291679·Phase 3·INTERVENTIONAL

Trial of Linaclotide in Patients With Chronic Idiopathic Constipation

Status

Completed

Phase

Phase 3

Enrollment

1,223

Locations

95

Results

Posted

Publications

0

Study summary

What the protocol is testing.

The objective of this trial was to determine the efficacy and safety of linaclotide 72 ug administered once daily to patients with chronic idiopathic constipation (CIC). The primary efficacy parameter is the percentage of participants in each dosing group that meet the protocol definition for complete spontaneous bowel movement (CSBM) Overall Responder.

Full detailed description

The trial also included a 145 ug linaclotide treatment arm (an FDA-approved dose for CIC) as an established positive control to validate the study design.

Interventions

Treatment arms and agents.

DRUG

Linaclotide

DRUG

Matching Placebo

Timeline

From registration to results.

  1. First posted

    Nov 14, 2014

  2. Study start

    Oct 2014

  3. Primary completion

    Aug 2015

  4. Study completion

    Aug 2015

  5. Results posted

    May 19, 2017

  6. Registry updated

    Jun 15, 2017

Outcomes

What the study measures.

Primary outcomes

Percentage of 12-Week CSBM Overall Responders

Time frame · Week 12

A 12-week CSBM Overall Responder is a participant who was a CSBM Weekly Responder for at least 9 of the 12 weeks of the Treatment Period. A CSBM Weekly Responder is a participant who had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline, and completed ≥ 4 IVRS calls for the specified week. A CSBM is defined as an SBM that is associated with a sense of complete evacuation. An SBM is defined as a bowel movement BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.

Secondary outcomes

Change From Baseline in 12-Week CSBM Frequency Rate

Time frame · Baseline, Week 1 to Week 12

A participant's 12-week CSBM Frequency Rate is the CSBM rate (CSBMs/week) calculated over the 12 weeks of the Treatment Period. A CSBM is defined as an SBM that is associated with a sense of complete evacuation. An SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.

Change From Baseline in 12-Week SBM Frequency Rate

Time frame · Baseline, Week 1 to Week 12

A participant's 12-week SBM Frequency Rate is the SBM rate (SBMs/week) calculated over the 12-weeks of the Treatment Period. An SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.

Change From Baseline in 12-Week Stool Consistency Score

Time frame · Baseline, Week 1 to Week 12

Stool consistency was measured daily using the 7-point ordinal Bristol Stool Form Scale (BSFS; 1 = separate hard lumps like nuts \[difficult to pass\]; 2 = sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges \[passed easily\]; 6 = fluffy pieces with ragged edges, a mushy stool; 7 = watery, no solid pieces \[entirely liquid\]). The participant's BSFS score for the Treatment Period is the average of the non-missing BSFS scores from the SBMs reported by the participant during the 12-week Treatment Period.

Change From Baseline in 12-Week Straining Score

Time frame · Baseline, Week 1 to Week 12

Straining was measured daily using a 5-point ordinal scale (1 = not at all; 2 = a little bit; 3 = a moderate amount; 4 = a great deal; 5 = an extreme amount). The participant's straining score for the Treatment Period is the average of the non-missing straining scores from the SBMs reported by the participant during the 12-week Treatment Period.

Percentage of 12-Week CSBM Overall Responders (>1 SBM/Week Subpopulation)

Time frame · Week 12

A 12-week CSBM Overall Responder is a participant who was a CSBM Weekly Responder for at least 9 of the 12 weeks of the Treatment Period. A CSBM Weekly Responder is a participant who had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline, and completed ≥4 IVRS calls for the specified week. A CSBM is defined as an SBM that is associated with a sense of complete evacuation. An SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.

Percentage of Month 1 CSBM Responders

Time frame · Month 1

A Month 1 CSBM Responder is a participant who is a CSBM weekly responder for at least 3 of the 4 weeks of Month 1 of the Treatment Period. A CSBM weekly responder is a participant who had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline based on a minimum of 4 complete IVRS calls for that week. A CSBM is defined as an SBM that is associated with a sense of complete evacuation. An SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.

Percentage of Month 2 CSBM Responders

Time frame · Month 2

A Month 2 CSBM Responder is a participant who is a CSBM weekly responder for at least 3 of the 4 weeks of Month 2 of the Treatment Period. A CSBM weekly responder is a participant who had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline based on a minimum of 4 complete IVRS calls for that week. A CSBM is defined as an SBM that is associated with a sense of complete evacuation. An SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.

Percentage of Month 3 CSBM Responders

Time frame · Month 3

A Month 3 CSBM Responder is a participant who is a CSBM weekly responder for at least 3 of the 4 weeks of Month 3 of the Treatment Period. A CSBM weekly responder is a participant who had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline based on a minimum of 4 complete IVRS calls for that week. A CSBM is defined as an SBM that is associated with a sense of complete evacuation. An SBM is defined as a BM that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.

Change From Baseline in 12-Week Abdominal Bloating

Time frame · Baseline, Week 1 to Week 12

Abdominal bloating was measured daily using an 11-point NRS (0 = none; 10 = very severe). The participant's abdominal bloating score for the Treatment Period is the average of the non-missing daily participant assessments of abdominal bloating scores reported during the 12-week Treatment Period.

Change From Baseline in 12-Week Abdominal Discomfort

Time frame · Baseline, Week 1 to Week 12

Abdominal discomfort was measured daily using an 11-point NRS (0 = none; 10 = very severe). The participant's abdominal discomfort score for the Treatment Period is the average of the non-missing daily participant assessments of abdominal discomfort scores reported during the 12-week Treatment Period.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Patient has completed a colonoscopy if one is needed according to the American Gastroenterological Association (AGA) criteria, with no clinically significant findings * Patient has no clinically significant findings on a physical examination and clinical laboratory tests * Patient meets protocol criteria for CIC: reports \< 3 bowel movements (BMs) per week and reports one or more of the following during ≥ 25% of BMs: straining, lumpy or hard stools, sensation of incomplete evacuation during the 3 months before the diagnosis with the onset at least 6 months before the diagnosis * Patient is compliant with daily interactive voice response system (IVRS) calls * Patient reports an average of \< 3 complete spontaneous BMs (CSBMs) and ≤ 6 SBMs per week by the IVRS over the 14 calendar days before the Randomization Visit and the calendar day of Randomization. Exclusion Criteria: * Patient has history of loose or watery stools * Patient has symptoms of or been diagnosed with irritable bowel syndrome (IBS) * Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility * Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments * Patient has Bristol Stool Form Scale score of 7 during Pretreatment period.

Study locations

95 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

Ironwood Investigational Site

Huntsville, Alabama, United States

Ironwood Investigational Site

Phoenix, Arizona, United States

Ironwood Investigational Site

Tucson, Arizona, United States

Ironwood Investigational Site

North Little Rock, Arkansas, United States

Ironwood Investigational Site

Anaheim, California, United States

Ironwood Investigational Site

Chula Vista, California, United States

Ironwood Investigational Site

Garden Grove, California, United States

Ironwood Investigational Site

La Mesa, California, United States

Ironwood Investigational Site

North Hollywood, California, United States

Ironwood Investigational Site

Orange, California, United States

Ironwood Investigational Site

San Diego, California, United States

Ironwood Investigational Site

Thousand Oaks, California, United States

Ironwood Investigational Site

Colorado Springs, Colorado, United States

Ironwood Investigational Site

Bristol, Connecticut, United States

Ironwood Investigational Site

Boynton Beach, Florida, United States

Ironwood Investigational Site

Coral Gables, Florida, United States

Ironwood Investigational Site

DeLand, Florida, United States

Ironwood Investigational Site

Hialeah, Florida, United States

Ironwood Investigational Site

Inverness, Florida, United States

Ironwood Investigational Site

Jupiter, Florida, United States

Ironwood Investigational Site

Kissimmee, Florida, United States

Ironwood Investigational Site

Lauderdale Lakes, Florida, United States

Ironwood Investigational Site

Miami, Florida, United States

Ironwood Investigational Site

Miami, Florida, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Linaclotide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.